Revenue segments as reported by the company.

Subscription services

Professional services and other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and admin

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veeva Systems

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Veeva Systems reports robust Q1 earnings, eyes growth opportunities

Veeva Systems delivered strong financial performance in Q1 2023, driven by robust execution and competitive wins. The company's focus on innovation, AI capabilities, and the transition to Vault CRM presents significant growth opportunities. However, challenges in the funding environment and customer migrations pose potential hurdles.

Veeva exceeds Q2 expectations, anticipates growth in clinical and data business

Veeva's Q2 performance exceeded expectations, leading to an increase in full-year guidance. The company's strengths lie in strong clinical activity, customer wins, and a focus on product excellence. However, challenges include migration costs, competitive landscape considerations, and marketing spend scrutiny. Veeva sees opportunities in M&A, minimal impact from R&D trends, and expansion of Veeva Link.

Veeva Systems surpasses Q3 expectations, eyes clinical data opportunity

Veeva Systems delivered a strong Q3 performance, with solid revenue and operating income. While facing challenges in billings and macroeconomic uncertainties, the company remains confident in its revenue target for fiscal year '25. The commitment from major enterprises and the potential in clinical data present significant opportunities for future growth.

Veeva Systems reports strong Q4 performance and forecasts $2.8B revenue

Veeva Systems showcases strong performance and strategic planning with revenue growth expectations of at least 15% in fiscal '24 and '25.
Positive feedback on product transitions and development, along with specialized sales teams, highlights market acceptance and innovation.
Challenges include short-term revenue impacts from timing-related issues and macro environment effects on customer spending.
Opportunities lie in revenue growth forecasts, product innovation, and market differentiation through new offerings and strategic deals.

Veeva Systems reports robust Q1 revenue growth and strategic focus

Veeva Systems' Q1 performance reflects strong revenue growth and a focus on customer-centric innovation. The company faces challenges in project scrutiny and competition but has opportunities in new product monetization and segment expansion.

Veeva Systems excels in Q2, eyes disciplined growth and innovation

Veeva Systems showcased robust financial performance, exceeding revenue and operating income targets, with a strong focus on customer success and product excellence.
While facing challenges such as migration costs and regulatory impacts, Veeva is well-positioned to leverage opportunities in disciplined M&A and product innovation.
The company's strategic growth initiatives, including Veeva Link expansion and CRM platform enhancements, aim to drive continued success and value for customers.

Veeva Systems posts solid Q3 results, eyes growth opportunities

Veeva Systems delivered a strong Q3 performance with solid revenue and operating income, showcasing financial stability and growth potential.
Despite challenges like trimmed billings and deal delays, Veeva remains confident in its fiscal year '25 revenue target, emphasizing strategic focus and operational efficiency.
The company's strengths in innovative products, strong partnerships, and global support ecosystem position it well for future growth and market leadership.
Opportunities in customer migration, AI integration, and market demand present avenues for Veeva to drive revenue growth and enhance its competitive positioning in the industry.

Veeva Systems excels in Q4 earnings, poised for strategic growth

Veeva Systems delivered strong financial performance in Q4 2024, showcasing revenue growth, operating income efficiency, and strategic product advancements.
The company's focus on innovation, customer success, and disciplined financial guidance positions it well for future growth and market leadership.
While facing challenges related to market uncertainties and operational considerations, Veeva remains resilient and poised to capitalize on opportunities for expansion and differentiation.
Overall, Veeva's Q4 earnings call highlights a balanced approach to growth, operational excellence, and strategic decision-making in a dynamic business environment.

Veeva Systems beats Q1 guidance, lowers full-year outlook amid challenges

Veeva Systems had a strong start to the year, exceeding Q1 guidance but lowering full-year revenue outlook due to macro challenges.
The company's performance in margin, client adoption, and innovation remains robust, with a focus on stability and predictability amidst industry challenges.
Challenges include AI disruption impacting plans, lower revenue guidance, and delays in funding benefits due to global conflicts and interest rate sensitivity.
Opportunities lie in new client bases, EDC deals progress, and the potential growth of Vault Basics and Link products in the market.

Veeva Systems excels in Q2, eyes strategic growth opportunities

Veeva Systems delivered a strong Q2 performance with revenue of $676 million and non-GAAP operating income of $280 million, driven by product expansions and customer wins.
The company's strengths lie in its comprehensive clinical suite, customer comfort with CRM solutions, and the importance of professional services for customer success.
Challenges include short-term billing growth constraints and the need for continuous product excellence, while opportunities exist in data architecture enhancement and upcoming Investor Day insights.

Veeva Systems excels in Q3 with strong revenue and strategic progress

Veeva Systems reported a strong Q3 performance with revenue of $699 million and non-GAAP operating income of $304 million, driven by milestones in Commercial and Services revenue beat.
The company's strengths lie in its competitive position, stable demand environment, and focus on enterprise capabilities, while challenges include maintaining growth momentum and expanding CRO revenue.
Opportunities for Veeva include leveraging its market position for growth, exploring new partnerships, and enhancing services revenue through successful project completions.
Overall, Veeva's performance reflects stability, strategic progress, and a focus on innovation and growth amidst a positive demand environment and competitive market landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

High multiples might deter investors from looking at Veeva stock. Multiples tell us the stock is expensive; however, sometimes multiples do not tell us the whole story, and that's the trick of investing.

Veeva Systems: The Stock Is Not Expensive

Doximity

A bull market is coming, and these are the stocks you'll want to own when it happens.

2 Outstanding Growth Stocks to Buy Ahead of the Next Bull Market

Biogen

BioNTech SE

Incyte

Inspire Medical Systems Inc

Eli Lilly

Viatris

Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

Adobe

Lam Research

Netflix

NVIDIA

Tencent Holdings Limited

While there's always a time and place to play it safe, investors at some point will likely need to consider the best growth stocks to buy to retire early. As the most recent World Cup demonstrated, some teams can successfully deploy defensive counterattacking strategies to win.

The 7 Best Growth Stocks to Buy to Retire Early

AUSTIN, Texas and PLEASANTON, Calif. , Dec. 14, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and CDISC are pleased to announce that Dan Crawford, Veeva Clinical Database (CDB) principal consultant, has been elected chair of the CDISC Advisory Council (CAC).

Veeva's Dan Crawford Elected Chair of CDISC Advisory Council

Salesforce

Both companies reported slowing financials, but this news captured the spotlight.

Salesforce and Veeva Systems Are Set to Sever Ties. Here's What Investors Need to Know

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both of its segments.

Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY23 View

Veeva Systems Inc. (NYSE:VEEV ) Q3 2023 Results Conference Call December 1, 2022 5:00 PM ET Company Participants Ato Garrett - SD, IR Peter Gassner - CEO Paul Shawah - EVP, Commercial Strategy Brent Bowman - CFO Conference Call Participants Ken Wong - Oppenheimer Brian Peterson - Raymond James Dylan Becker - William Blair Anne Samuel - JP Morgan Craig Hettenbach - Morgan Stanley Gabriela Borges - Goldman Sachs Joe Vruwink - Baird Ryan MacDonald - Needham & Company Tyler Radke - Citi Stephanie Davis - SVB Securities Brent Bracelin - Piper Sandler Rishi Jaluria - RBC Capital Markets Jack Wallace - Guggenheim Securities Brad Sills - Bank of America Saket Kalia - Barclays Operator Good afternoon. My name is Emma, and I will be your conference operator today.

Veeva Systems Inc. (VEEV) Q3 2023 Earnings Call Transcript

Veeva (VEEV) delivered earnings and revenue surprises of 5.61% and 1.21%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates

Shares of Veeva Systems Inc. VEEV, +0.56% dropped nearly 6% in the extended session Thursday after the cloud-computing company reported quarterly earnings above expectations but guided for a weaker-than-expected current quarter. Veeva earned $108.5 million, or 67 cents a share, in the quarter, compared with $105.9 million, or 65 cents a share, in the year-ago period.

Veeva stock drops in the extended session after weaker-than-forecast quarterly guidance

Total Revenues of $552.4M, up 16% Year Over Year; Subscription Services Revenues of $441.6M, up 16% Year Over Year PLEASANTON, Calif. , Dec. 1, 2022 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2022.

Veeva Announces Fiscal 2023 Third Quarter Results

Exact Sciences

Novo Nordisk

All offer products that are invaluable to their respective audiences.

3 Healthcare Stocks That Could Set You Up For Life

CrowdStrike

Dollar General

Intuit

Kroger

Marvell Technology

Snowflake

Synopsys

Workday

The third quarter 2022 earnings season isn't over yet, but more than 90% of the companies have already reported their earnings so far.

These Are Ten Big Companies Releasing Earnings Next Week

Leading companies leverage real-time insights on share of scientific voice and product sentiment to power more relevant medical communications PLEASANTON, Calif. , Nov. 23, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced three of the top ten biopharmas now use the recently released Veeva Link Scientific Awareness for real-time intelligence on product awareness and sentiment.

Top Biopharmas Elevate Medical Engagement with Veeva Link Scientific Awareness

More than half of accessible HCPs engage via video and in-person Access is selective as most meet with three companies or less PLEASANTON, Calif. , Nov. 15, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today released the latest Veeva Pulse Field Trends Report, the largest and most complete analysis of healthcare professional (HCP) access across the biopharma industry.

Veeva Pulse Shows Post-Pandemic HCP Access Nearing 80% in Key Specialties Driven by Digital Engagement

Apple

Abbott Labs

Cognizant Technology Solutions

Microsoft

Ross Stores

While it's tempting to target the flavors of the week during a market correction, investors ought to spare some time for no-brainer blue-chip stocks to buy for 2023 and beyond. Indeed, the broader market and economic dynamics encourage retail investors to think about value and stability over growth.

7 No-Brainer Blue-Chip Stocks to Buy for 2023 and Beyond

Fintel reports Morgan Stanley has filed a 13G/A form with the SEC disclosing ownership of 1,220,689 shares of Veeva Systems Inc (VEEV).

Morgan Stanley Makes Cuts in Veeva Systems (VEEV)

PLEASANTON, Calif. , Nov. 9, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its third quarter, which ended October 31, 2022, after market close on December 1, 2022.

Veeva to Release Fiscal 2023 Third Quarter Results on December 1, 2022

Veeva Systems held its 2022 Investor Day last week. The company went into depth about its product portfolio and opportunities going forward.

Veeva Systems: An Ambitious Goal Within Reach

Merck

Ten-year partnership will help Merck reduce operational costs, deliver value to patients, and optimize the healthcare professional and patient experience PLEASANTON, Calif. , Nov. 1, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a ten-year strategic partnership agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada, that builds on the existing 12-year partnership between the companies.

Veeva and Merck Form Long-Term Strategic Partnership

Veeva looks like a fat pitch to swing at right now.

Veeva Systems Stock Hasn't Been This Cheap in Years -- Is It Time to Buy the Dip?

Veeva has carved out a niche for itself in life sciences with a wide moat. Growth has slowed recently, and the pathway to reacceleration is unclear.

Veeva: Niche SaaS Doesn't Hit The Mark For Me

New unified CRM and content management application delivers industry-specific capabilities for coordinated and effective engagement PLEASANTON, Calif. , Oct. 24, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Vault CRM for Medtech, a unified customer relationship management (CRM) and content management application built for medtech sales teams, key account managers, and medical affairs professionals.

Veeva Introduces Veeva Vault CRM for Medtech

Medtronic

Both have lagged the market in the past year.

2 Stocks to Buy and Forget in This Bear Market

Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

News for Veeva Systems Stock (VEEV)